PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23197749-0	2012	Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.	polyglutamine	42-47	ataxin 2	Homo sapiens	13-21	
23197749-1	2012	OBJECTIVE: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in the ataxin-2 (ATXN-2) gene are a risk factor for amyotrophic lateral sclerosis (ALS).	polyglutamine	61-74	ataxin 2	Homo sapiens	101-109	
23197749-1	2012	OBJECTIVE: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in the ataxin-2 (ATXN-2) gene are a risk factor for amyotrophic lateral sclerosis (ALS).	polyglutamine	61-74	ataxin 2	Homo sapiens	111-117	
23197749-1	2012	OBJECTIVE: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in the ataxin-2 (ATXN-2) gene are a risk factor for amyotrophic lateral sclerosis (ALS).	polyglutamine	76-81	ataxin 2	Homo sapiens	101-109	
23197749-1	2012	OBJECTIVE: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in the ataxin-2 (ATXN-2) gene are a risk factor for amyotrophic lateral sclerosis (ALS).	polyglutamine	76-81	ataxin 2	Homo sapiens	111-117	
23197749-2	2012	This work was undertaken with the aim to investigate the frequency of ataxin-1 (ATXN-1) and ATXN-2 PolyQ expansions in a cohort of patients with sporadic ALS (sALS) and patients with familial ALS (fALS) from southern Italy.	polyglutamine	99-104	ataxin 2	Homo sapiens	92-98	
23197749-4	2012	RESULTS: We found significantly higher intermediate PolyQ expansions >= 32 for ATXN-1 alleles and >= 28 for ATXN-2 alleles in the sALS cohort (ATXN-1: ALS, 7.07% vs controls, 2.38%; p = 0.0001; ATXN-2: ALS, 2.72% vs controls, 0.5%; p = 0.001).	polyglutamine	52-57	ataxin 2	Homo sapiens	194-200	
23197749-7	2012	CONCLUSIONS: Both ATXN-1 and ATXN-2 PolyQ intermediate expansions are independently associated with an increased risk for ALS.	polyglutamine	36-41	ataxin 2	Homo sapiens	29-35